While some cancers acquire amplification or overexpression of PHGDH, the first and rate-limiting step in this pathway, other types of cancers activate oncogenes such as MYC, MDM2, KRAS, and NRF2, leading to increased SSP enzyme expression (19, 23–26). The gene discussed is MYC; the disease is cancer.